Nicole Lamanna, MD

Articles

Non-Covalent BTK Inhibitors in CLL: Updates from Clinical Trials With Pirtobrutinib

February 8th 2023

Expert perspectives on the role of non-covalent BTK inhibitors in managing patients diagnosed with chronic lymphocytic leukemia.

Chronic Lymphocytic Leukemia: Real World and QoL Evidence With BTKi

February 8th 2023

A panel of key opinion leaders elucidates real-world data with BTK inhibitors in CLL and considers the importance of patient-reported outcomes on quality of life.

Selecting the Appropriate BTKi in Chronic Lymphocytic Leukemia

February 1st 2023

Comprehensive perspectives on clinical factors that help to inform the selection of appropriate BTK inhibitor therapy for patients with chronic lymphocytic leukemia.

Head-to-Head Trials of BTKi in Chronic Lymphocytic Leukemia

February 1st 2023

Shared insight on and reactions to head-to-head comparison trials between novel BTK inhibitors in the setting of chronic lymphocytic leukemia.

BTK Inhibitors in Relapsed/Refractory Chronic Lymphocytic Leukemia

January 25th 2023

Switching focus to the second-line setting, expert hematologist-oncologists evaluate the continued role of BTK inhibitors in chronic lymphocytic leukemia.

Second Generation BTKi in CLL: First-Line Treatment With Acalabrutinib or Zanubrutinib

January 25th 2023

Centering discussion on second-generation BTK inhibitors, expert panelists review clinical data behind first-line acalabrutinib and zanubrutinib, respectively.

Chronic Lymphocytic Leukemia: Role of First-Generation BTK Inhibitors

January 18th 2023

A brief review of first-line BTK inhibition in chronic lymphocytic leukemia following the advent of ibrutinib, along with considerations for minimal residual disease testing in this setting.

Brief Overview of Chronic Lymphocytic Leukemia

January 18th 2023

Expert hematologist-oncologist Sonali Smith, MD, shares a brief overview of chronic lymphocytic leukemia (CLL), highlighting incidence, prognosis, and molecular subsets.

Zanubrutinib Demonstrates Superior Progression-Free Survival Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Results from Final Analysis of ALPINE Randomized Phase 3 Study

January 5th 2023

Nicole Lamanna, MD, reviews the results of the phase 3 study evaluating the use of zanubrutinib versus ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Optimizing the Treatment of CLL With Novel Therapies

March 14th 2022

Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.

CAR T-Cell Therapies in CLL

March 14th 2022

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

PI3K Inhibitors for CLL

March 7th 2022

A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.

Noncovalent BTK Inhibitors in CLL

March 7th 2022

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

Novel Therapies for CLL: Sequencing Strategies

February 28th 2022

Factors that impact decisions for frontline and subsequent lines of therapy for patients with chronic lymphocytic leukemia.

Treating CLL With Anti-CD20 Antibody Regimens

February 21st 2022

Recommendations for combining an anti-CD20 antibody with a Bruton tyrosine kinase inhibitor or venetoclax in doublet or triplet regimens for the treatment for chronic lymphocytic leukemia (CLL).

Chemotherapy-Free Regimens as Frontline Therapy in CLL

February 21st 2022

Key takeaways of the CLL13 (GAIA) clinical trial based on highlights presented at ASH 2021.

Fixed-Duration Therapy in Relapsed/Refractory CLL: Ibrutinib Plus Venetoclax

February 14th 2022

Considerations for treating patients with relapsed/refractory chronic lymphocytic leukemia with the combination of ibrutinib and venetoclax.

Ibrutinib Therapy for CLL: Long-Term Data

January 24th 2022

Reactions to longer-term follow-up data presented in 2021 on the use of ibrutinib as frontline treatment for patients with chronic lymphocytic leukemia.

BTK Inhibitors as Frontline Therapy for CLL

January 24th 2022

The rationale for using Bruton tyrosine kinase inhibitors, such as the first-generation option, ibrutinib, as first-line treatment for chronic lymphocytic leukemia.

Dr. Lamanna Discusses the MURANO Trial in CLL

January 2nd 2019

Nicole Lamanna, MD, associate professor of medicine, Hematologic Malignancies Section, Division of Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, discusses the MURANO trial in patients with chronic lymphocytic leukemia.